Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review.

Authors:
Jollant F; Colle R; Nguyen TML; Corruble E; Gardier AM and 3 more

Journal:
Ther Adv Psychopharmacol

Publication Year: 2023

DOI:
10.1177/20451253231151327

PMCID:
PMC9912570

PMID:
36776623

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Ther Adv Psychopharmacol

Abbreviation: Ther Adv Psychopharmacol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Drug safety in older patients with alcohol use disorder: a retrospective cohort study.
Schröder S; Westhoff MS; Pfister T and 6 more (2024) - Transparency Score: 3/6
Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous k…
Yan R; Marshall T; Khullar A and 5 more (2024) - Transparency Score: 3/6
Patients' awareness of recovery mediates the link between clinical and level of functional remissio…
Mallet J; Dondé C; Dubertret C and 1 more (2024) - Transparency Score: 3/6
Altered whole-brain resting-state functional connectivity and brain network topology in typhoon-rel…
Chen HJ; Ke J; Qiu J and 6 more (2023) - Transparency Score: 3/6
Efficacy of intraoperative subanesthetic dose of ketamine/esketamine in preventing postoperative co…
Zhou N; Chen C; Liu Y and 2 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MW was previously involved in a clinical trial on ketamine in treatment-resistant depression in collaboration with Janssen Pharmaceuticals (Trial ID: DRKS00003527). MA declares fees from AstraZeneca and Lundbeck and has been invited to congresses by Janssen-Cilag, Otsuka, Lundbeck, Servier, and AstraZeneca. All other authors have no competing interests."

Evidence found in paper:

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025